Biosimilar Approval: How FDA Reviews Biologic Alternatives in 2026
The FDA's 2025 overhaul of biosimilar approval removes routine clinical trials, relying instead on advanced analytics to prove similarity. This shift could cut costs, speed up access, and expand patient options for expensive biologic drugs.